A Comparison of Soft-tissue Substitutes

Özgentaş, H. Ege; Pindur, Ales; Spira, Melvin; Liu, Bingci; Shenaq, Saleh M.

doi:10.1097/00000637-199408000-00009

Cited by 11 publications

(9 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Several methods were used for defect coverage such as lyophilized dura (Ernestus et al 1995), titanium meshes (Park et al 2001) or synthetic resorbable or non‐resorbable scaffolds (Morain et al 1987; Nakajima et al 2001). These materials hold the risk of transmitting infections (Radbauer et al 1998) or to induce a foreign body reaction resulting in an increased scare formation (Ozgentas et al 1994). Therefore, the biocompatibility of the used material must carefully be investigated before clinical use.…”

mentioning

confidence: 99%

“…Especially in craniotomies with large defects, coverage with autogenic tissue is not always possible. Several methods were used for defect coverage such as lyophilized dura (Ernestus et al 1995), titanium meshes (Park et al 2001) (Radbauer et al 1998) or to induce a foreign body reaction resulting in an increased scare formation (Ozgentas et al 1994). Therefore, the biocompatibility of the used material must carefully be investigated before clinical use.…”

mentioning

confidence: 99%

See 1 more Smart Citation

Biodegradable polylactide membranes for bone defect coverage: biocompatibility testing, radiological and histological evaluation in a sheep model

Schmidmaier

Baehr

Mohr

et al. 2006

Clinical Oral Implants Res

View full text Add to dashboard Cite

Large bony defects often show a delayed healing and have an increasing risk of infection. Several materials are used for the coverage of large defects. These materials must be biocompatible, easy to use, and must have an appropriate stability to present a mechanical hindrance. Aim of this study was to investigate two different biodegradable membranes for defect coverage in a sheep model. Round cranial defects (1.5 cm diameter) were created in sheep. Six different treatments were investigated: defects without membrane, defects covered with a poly(D,L-lactide) or with a 70/30 poly(L/D,L-lactide) membrane and all defects with or without spongiosa filling. The sheep were sacrificed 12 or 24 weeks postoperatively. Bone formation in the defects was quantified by computer-assisted measurements of the area of the residual defect on CT radiographs. Histomorphometry and host-tissue response were evaluated by light microscopy. The biocompatibility was investigated by analyzing the amount of osteoclasts and foreign body cells. Both membranes served as a mechanical hindrance to prevent the prolapse of soft tissue into the defect. The biocompatibility test revealed no differences in the amount and distribution of osteoclasts at the two investigated time points and between the investigated groups. No negative effect on the tissue regeneration was detectable between the investigated groups related to the type of membrane, but a foreign body reaction around the two membrane types was observed. In the membrane-covered defects, the spongiosa showed a progressing remodeling to the native bony structure of the cranium. The groups without spongiosa partly revealed new bone formation, without complete bridging in any group or at any time point. Comparing the 12 and 24 weeks groups, an increased bone formation was detectable at the later time point. In conclusion, the results of the present in vivo study reveal a good biocompatibility and prevention of soft tissue prolapse of the two used membranes without differences between the membranes. An enhanced remodeling of the spongiosa into native bony structures under the membranes was detectable, but no osteopromoting effect was observed due to the membranes.

show abstract

mentioning

confidence: 99%

mentioning

confidence: 99%

Biodegradable polylactide membranes for bone defect coverage: biocompatibility testing, radiological and histological evaluation in a sheep model

Schmidmaier

Baehr

Mohr

et al. 2006

Clinical Oral Implants Res

View full text Add to dashboard Cite

show abstract

“…Rats have been studied previously to investigate the persistence and tissue compatibility of Zyderm II and Zyplast. 18 Subcutaneous implantation of Zyderm II and Zyplast showed more than 75% residual material with minimal inflammation between 6 months and 1 year. However, “dense fibrous encapsulation” was noted with occasional calcification by that time.…”

Section: Discussionmentioning

confidence: 95%

Injectability and Tissue Compatibility of Poly-(N-Vinyl-2-Pyrrolidone) in the Skin of Rats: A Pilot Study

Arpey

Chang

Whitaker

2000

Dermatologic Surgery

View full text Add to dashboard Cite

Poly-(N-vinyl-2-pyrrolidone) is easy to inject intracutaneously and is well tolerated in the rat model. Short-term volume retention is good. Histopathology suggests a subclinical inflammatory reaction expected with implantation of a synthetic substance into the skin. Additional studies are necessary to investigate the continued persistence of the hydrogel and its long-term effects on surrounding tissue.

show abstract

“…Bovine injectable collagen (Zyderm I 1 , Zyderm II 1 , and Zyplast 1 collagen implants; Inamed Corporation, Santa Barbara, CA) has been used extensively in the United States, Japan, Europe, and Hong Kong for these purposes. 7 With the growing use of bovine collagen implants, questions have been raised regarding their immunogenicity in humans. Although these bovine collagen preparations are of low immunogenicity, they are still foreign proteins.…”

mentioning

confidence: 99%

“…8 Many investigators believe the use of human-based collagen will overcome this shortcoming. 7,9 This article describes the preclinical and clinical experience with a type I and type III injectable human collagen product derived from human sources (containing type I and type III collagen in a proportion of 44:56) utilized as a dermal filler. Our results demonstrate that type I and type III injectable human collagen is a safe and reliable biomaterial that can easily be used for soft tissue augmentation.…”

mentioning

confidence: 99%

The Use of Type I and Type III Injectable Human Collagen for Dermal Fill: 10 Years of Clinical Experience in China

Liu¹,

et al. 2005

Seminars in Plastic Surgery

Self Cite

View full text Add to dashboard Cite

This article reports preclinical and clinical experience with a type I and type III injectable human collagen product derived from human sources (containing type I and type III collagen in a proportion of 44:56) utilized as a dermal filler. The preclinical study involves experiments characterizing the histological changes observed after type I and type III injectable human collagen injection in rats. The clinical trial is a study of 123 patients treated with type I and type III injectable human collagen for pitting skin deficiencies including furrow, superficial scar, and superficial atrophy. Histological observations from the preclinical study revealed that type I and type III injectable human collagen persisted for at least a year. The clinical trial showed that most patients were satisfied with the results, and a rating of excellent or good was achieved 90.2% of the time. The positive results lasted about 9 months after the first injection, 12 months after the second injection, and 18 months after the third injection. Reported side effects were slight redness and discomfort at or near the injection site. Type I and type III injectable human collagen is a safe and reliable biomaterial that can easily be used for soft tissue augmentation.

show abstract

A Comparison of Soft-tissue Substitutes

Cited by 11 publications

References 0 publications

Biodegradable polylactide membranes for bone defect coverage: biocompatibility testing, radiological and histological evaluation in a sheep model

Biodegradable polylactide membranes for bone defect coverage: biocompatibility testing, radiological and histological evaluation in a sheep model

Injectability and Tissue Compatibility of Poly-(N-Vinyl-2-Pyrrolidone) in the Skin of Rats: A Pilot Study

The Use of Type I and Type III Injectable Human Collagen for Dermal Fill: 10 Years of Clinical Experience in China

Contact Info

Product

Resources

About